Ion Beam Applications SA IBA (GB:0GZK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PanTera, a joint venture of IBA (Ion Beam Applications S.A), has raised EUR 93 million in an oversubscribed Series A funding round, led by EQT Life Sciences, to accelerate the production of actinium-225, a critical component for new targeted cancer treatments. The financing, which is the largest Series A in Belgium’s life sciences sector, brings the total raised to EUR 134 million and will support the construction of a new production facility. With IBA’s participation reducing to 31.3%, the transaction will positively impact IBA’s profits by approximately EUR 23 million over the next three years.
For further insights into GB:0GZK stock, check out TipRanks’ Stock Analysis page.
